These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 3770104

  • 1. Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion.
    Corden BJ.
    Exp Hematol; 1986 Nov; 14(10):971-4. PubMed ID: 3770104
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG, Gupta G, Estes WE, Rosenkrantz H, Metterville JJ, Crumbliss AL, Palmer RA, Nordquest KW, Hardy KA, Whitcomb DR, Byers BR, Arceneaux JE, Gaines CG, Sciortino CV.
    J Pharmacol Exp Ther; 1979 Jan; 208(1):12-8. PubMed ID: 759605
    [Abstract] [Full Text] [Related]

  • 4. Iron retention and excretion in mice transfused with homologous or heterologous blood and treated with chelators.
    Gralla EJ, Burgess DH.
    Methods Find Exp Clin Pharmacol; 1982 Jan; 4(3):151-9. PubMed ID: 7121126
    [Abstract] [Full Text] [Related]

  • 5. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH.
    Curr Top Hematol; 1978 Jan; 1():127-50. PubMed ID: 400529
    [No Abstract] [Full Text] [Related]

  • 6. Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells.
    Parkes JG, Hussain RA, Olivieri NF, Templeton DM.
    J Lab Clin Med; 1993 Jul; 122(1):36-47. PubMed ID: 8320489
    [Abstract] [Full Text] [Related]

  • 7. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
    Lau EH, Cerny EA, Wright BJ, Rahman YE.
    J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
    [Abstract] [Full Text] [Related]

  • 8. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
    Graziano JH, Grady RW, Cerami A.
    J Pharmacol Exp Ther; 1974 Sep; 190(3):570-5. PubMed ID: 4416298
    [No Abstract] [Full Text] [Related]

  • 9. The development of new iron-chelating drugs.
    Grady RW, Graziano JH, Akers HA, Cerami A.
    J Pharmacol Exp Ther; 1976 Feb; 196(2):478-85. PubMed ID: 1255491
    [Abstract] [Full Text] [Related]

  • 10. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR, Mahony BS, Githens JH, Rhoades ED.
    Am J Pediatr Hematol Oncol; 1982 Feb; 4(2):115-23. PubMed ID: 7114394
    [Abstract] [Full Text] [Related]

  • 11. IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture.
    Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C.
    Blood; 1997 Nov 15; 90(10):4180-7. PubMed ID: 9354689
    [Abstract] [Full Text] [Related]

  • 12. Mode of action of butoxyethanol-induced mouse liver hemangiosarcomas and hepatocellular carcinomas.
    Klaunig JE, Kamendulis LM.
    Toxicol Lett; 2005 Mar 28; 156(1):107-15. PubMed ID: 15705491
    [Abstract] [Full Text] [Related]

  • 13. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA.
    J Lab Clin Med; 1993 Jul 28; 122(1):48-54. PubMed ID: 8320490
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007 Jul 28; 26 Suppl 1():3-106. PubMed ID: 17365137
    [Abstract] [Full Text] [Related]

  • 16. The development of new iron-chelating drugs. II.
    Grady RW, Graziano JH, White GP, Jacobs A, Cerami A.
    J Pharmacol Exp Ther; 1978 Jun 28; 205(3):575-65. PubMed ID: 660531
    [Abstract] [Full Text] [Related]

  • 17. Pulmonary toxicity of deferoxamine in iron-poisoned mice.
    Adamson IY, Sienko A, Tenenbein M.
    Toxicol Appl Pharmacol; 1993 May 28; 120(1):13-9. PubMed ID: 8511775
    [Abstract] [Full Text] [Related]

  • 18. Signs of iron deficiency in copper-deficient rats are not affected by iron supplements administered by diet or by injection.
    Reeves PG, DeMars LC.
    J Nutr Biochem; 2006 Sep 28; 17(9):635-42. PubMed ID: 16781861
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R.
    Arch Intern Med; 1985 Jul 28; 145(7):1217-21. PubMed ID: 3925909
    [Abstract] [Full Text] [Related]

  • 20. Uptake of iron by isolated rat hepatocytes from a hydrophilic impermeant ferric chelate, Fe(III)-DTPA.
    Scheiber B, Goldenberg H.
    Arch Biochem Biophys; 1996 Feb 15; 326(2):185-92. PubMed ID: 8611022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.